INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of …
RCKT Stock Tanks on Patient Death in Danon Disease Study Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts…
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and…
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.…
Rocket Pharmaceuticals Q3 Earnings Beat, Pipeline in Focus RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.…
Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06% The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…
Rockets (RCKT) Q1 Loss Narrower Than Expected, Sales Nil Rocket Pharmaceuticals (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…
Rocket Pharmaceuticals director sells over $7.79 million in company stock By Investing.com Rocket Pharmaceuticals director sells over $7.79 million in company stock…
Rocket Pharmaceuticals executive sells over $69k in company stock By Investing.com Rocket Pharmaceuticals executive sells over $69k in company stock…
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 Rocket Pharmaceuticals (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…